West Pharmaceutical Services Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $154.0M | $138.8M | $132.1M | $140.0M | $131.8M | $89.8M | $130.1M | $136.0M |
| Depreciation & Amortization | $46.2M | $45.2M | $47.0M | $43.0M | $41.4M | $40.0M | $40.7M | $40.2M |
| Depreciation | $45.7M | $44.6M | $46.4M | $42.3M | $40.8M | $39.1M | $39.8M | $39.3M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $10.9M | $6.6M | $6.7M | $8.4M | $7.4M | $1.3M | $4.3M | $5.1M |
| Net Cash from Operating Activities | $124.0M | $89.9M | $251.1M | $197.2M | $177.1M | $129.4M | $190.1M | $180.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $43.2M | $42.7M | $76.1M | $63.3M | $75.2M | $71.3M | $104.9M | $81.3M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-43.2M | $-42.7M | $-76.1M | $-63.3M | $-75.2M | $-71.3M | $-104.8M | $-82.1M |
| Financing Activities | ||||||||
| Dividends Paid | $15.7M | $15.8M | $15.8M | $15.1M | $15.1M | $15.2M | $15.3M | $14.5M |
| Stock Repurchases | $156.7M | $297.6M | $0 | $0 | $500.0K | $133.5M | $54.4M | $52.4M |
| Net Cash from Financing Activities | $-164.8M | $-308.7M | $-11.7M | $-11.5M | $-14.9M | $-147.0M | $-68.9M | $-64.4M |
| Net Change in Cash | $-85.6M | $-269.9M | $162.8M | $118.8M | $105.5M | $-80.4M | $-6.3M | $44.7M |
| Free Cash Flow | $80.8M | $47.2M | $175.0M | $133.9M | $101.9M | $58.1M | $85.2M | $98.8M |